News

News 13.02.2026 InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed a partnership with PharmaNest Inc, a Princeton, NJ-based digital pathology company. This partnership uniquely positions InSphero’s in the space of the translational application of machine learning tools in combination with human pre-clinical models to decipher complex pathological phenotypes for the identification of effective therapies. A key challenge of these current unmet clinical needs is the prediction of the drug efficacy of complex fibrotic phenotypes in clinical...

News 11.02.2026 European microphysiological systems (MPS) industry leaders, Alveolix (Switzerland); BiomimX (Italy); Chiron (Netherlands); Dynamic42 (Germany); InSphero (Switzerland); MIMETAS (Netherlands); NETRI (France), React4Life (Italy) and TissUse (Germany), are announcing today the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world’s first industry association dedicated to represent MPS providers. IAMPS’ mission is...

News 10.02.2026 Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality...

News 02.02.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...

News 01.02.2026 CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration...